Alnylam Discusses RNAi Delivery - - BioPharm International

ADVERTISEMENT

Alnylam Discusses RNAi Delivery



Alnylam Pharmcaeuticals, a company specializing in RNA-interference therapeutics, talks to BioPharm International's Amy Ritter about its RNAi delivery system and its early-stage clinical pipeline.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here